Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changming Xia

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
International Archives of Allergy and Immunology|September 25, 2025
Prevalence of Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease among Patients with Chronic Rhinosinusitis with Nasal Polyps in the Global AROMA RegistryMartin Desrosiers, Tanya M Laidlaw, Andrew A White, et al.
ERJ Open Research|November 29, 2023
Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid doseChristian Domingo, Klaus F Rabe, David Price, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 12, 2026
Protocol for a multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)Simon Couillard, Nayia Petousi, Sanjay Ramakrishnan, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 29, 2024
Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: A Post Hoc Analysis of VOYAGEDaniel J Jackson, Eckard Hamelmann, Graham Roberts, et al.
Journal of Asthma and Allergy|February 13, 2024
Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE StudyTheresa W Guilbert, Kevin R Murphy, Eckard Hamelmann, et al.
American Journal of Rhinology & Allergy|September 20, 2024
Association Between Smell Loss, Disease Burden, and Dupilumab Efficacy in Chronic Rhinosinusitis with Nasal PolypsZachary M Soler, Zara M Patel, Joaquim Mullol, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 18, 2026
Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization LevelWanda Phipatanakul, Nikolaos G Papadopoulos, Vivian Hernandez-Trujillo, et al.
The Journal of Allergy and Clinical Immunology|November 16, 2025
Transient early blood eosinophil increases do not affect dupilumab's long-term efficacy in patients with moderate-to-severe asthmaIan D Pavord, Njira L Lugogo, Mario Castro, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|August 6, 2025
Impact of asthma age of onset or duration on efficacy of dupilumab in moderate-to-severe type 2 asthmaWilliam W Busse, Monica Kraft, Christian Domingo, et al.
Advances in Therapy|December 9, 2024
Baseline Characteristics of Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global RegistryNjira L Lugogo, Xavier Soler, Yasuhiro Gon, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
International Archives of Allergy and Immunology|September 25, 2025
Prevalence of Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease among Patients with Chronic Rhinosinusitis with Nasal Polyps in the Global AROMA RegistryMartin Desrosiers, Tanya M Laidlaw, Andrew A White, et al.
ERJ Open Research|November 29, 2023
Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid doseChristian Domingo, Klaus F Rabe, David Price, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 12, 2026
Protocol for a multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)Simon Couillard, Nayia Petousi, Sanjay Ramakrishnan, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 29, 2024
Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: A Post Hoc Analysis of VOYAGEDaniel J Jackson, Eckard Hamelmann, Graham Roberts, et al.
Journal of Asthma and Allergy|February 13, 2024
Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE StudyTheresa W Guilbert, Kevin R Murphy, Eckard Hamelmann, et al.
American Journal of Rhinology & Allergy|September 20, 2024
Association Between Smell Loss, Disease Burden, and Dupilumab Efficacy in Chronic Rhinosinusitis with Nasal PolypsZachary M Soler, Zara M Patel, Joaquim Mullol, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 18, 2026
Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization LevelWanda Phipatanakul, Nikolaos G Papadopoulos, Vivian Hernandez-Trujillo, et al.
The Journal of Allergy and Clinical Immunology|November 16, 2025
Transient early blood eosinophil increases do not affect dupilumab's long-term efficacy in patients with moderate-to-severe asthmaIan D Pavord, Njira L Lugogo, Mario Castro, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|August 6, 2025
Impact of asthma age of onset or duration on efficacy of dupilumab in moderate-to-severe type 2 asthmaWilliam W Busse, Monica Kraft, Christian Domingo, et al.
Advances in Therapy|December 9, 2024
Baseline Characteristics of Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global RegistryNjira L Lugogo, Xavier Soler, Yasuhiro Gon, et al.
Pageof 4